<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18191" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Behcet Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adil</surname>
            <given-names>Abdullah</given-names>
          </name>
          <aff>Allama Iqbal Medical College/JHL, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Quint</surname>
            <given-names>Jessilin M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdullah Adil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jessilin Quint declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18191.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Behcet disease was first described in 1937 by Hulusi Beh&#x000e7;et from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum. Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology. It is characterized by mucocutaneous manifestations, including recurrent oral and genital ulcerations, ocular manifestations, especially chronic relapsing uveitis, and systemic vasculitis involving arteries and veins of all sizes. It is also known as Behcet syndrome and malignant aphthosis. This activity describes the pathophysiology, etiology, presentation, and diagnosis of Behcet disease and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of Behcet disease.</p></list-item><list-item><p>Review the presentation of a patient with Behcet disease.</p></list-item><list-item><p>Outline the management options available for Behcet disease.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care and outcomes in patients with Behcet disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18191&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18191">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18191.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Behcet disease was first described in 1937 by&#x000a0;Hulusi Beh&#x000e7;et from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum.<xref ref-type="bibr" rid="article-18191.r1">[1]</xref> Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology. It is characterized by mucocutaneous manifestations, including recurrent oral and genital ulcerations, ocular manifestations, especially chronic relapsing uveitis, and systemic vasculitis involving arteries and veins of all sizes. It is also known as Behcet syndrome and malignant aphthosis.</p>
      </sec>
      <sec id="article-18191.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiological basis of Behcet disease remains unknown, although genetics and environmental factors have been found to play a role.</p>
        <p>Increased prevalence along the "Silk Route" and familial aggregation suggest a genetic element, although Behcet disease does not follow a mendelian inheritance. The most frequent association is with carriers of HLA-B51/B5, who are at high risk for developing Behcet disease compared to non-carriers.<xref ref-type="bibr" rid="article-18191.r2">[2]</xref> HLA B51 is a common genetic factor prevalent in Japanese, middle eastern, and Turkish populations. Several other genes have been identified, including&#x000a0;tumor necrosis factor (TNF), heat shock proteins, and&#x000a0;major histocompatibility complex class I chain-related genes. Still, their independent contribution to the development of&#x000a0;Behcet disease is debatable.<xref ref-type="bibr" rid="article-18191.r3">[3]</xref></p>
        <p>Exposure to infectious agents, especially&#x000a0;hypersensitivity to&#x000a0;<italic toggle="yes">Streptococcus sanguinis</italic>&#x000a0;antigens, has suggested a pathological role.<xref ref-type="bibr" rid="article-18191.r4">[4]</xref><xref ref-type="bibr" rid="article-18191.r5">[5]</xref> While many other infectious agents, including&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>, Herpes simplex virus type 1, and&#x000a0;<italic toggle="yes">Prevotella</italic>&#x000a0;species, have been suggested as potential culprits, their direct association with the development of Behcet disease has not been confirmed.<xref ref-type="bibr" rid="article-18191.r6">[6]</xref> The current belief is that exposure to an infectious or an external agent somehow initiates an auto-inflammatory response in genetically predisposed individuals.</p>
      </sec>
      <sec id="article-18191.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Behcet disease usually affects young adults 20 to 40 years of age and is also seen in children less frequently.<xref ref-type="bibr" rid="article-18191.r7">[7]</xref><xref ref-type="bibr" rid="article-18191.r8">[8]</xref>&#x000a0;Both genders are equally affected by the disease; a male predominance is observed in Arab populations, while female&#x000a0;predominance&#x000a0;is evident in Korea, China, the United States, and some northern European countries. The disease has a more severe course in males and younger populations.<xref ref-type="bibr" rid="article-18191.r9">[9]</xref>&#x000a0;Most cases are sporadic, although familial clusters are also reported.<xref ref-type="bibr" rid="article-18191.r10">[10]</xref>&#x000a0;Genetic anticipation, described as the earlier onset of disease in successive generations, has also been described.<xref ref-type="bibr" rid="article-18191.r11">[11]</xref></p>
        <p>The geographic pattern of the disease suggests a distribution along the ancient "Silk Route" with the highest incidence in the Middle and the Far East.&#x000a0;Turkey has the highest prevalence affecting 420 people per 100,000 population.<xref ref-type="bibr" rid="article-18191.r12">[12]</xref> In the United States, the prevalence is 5.2 people per 100,000 population.<xref ref-type="bibr" rid="article-18191.r13">[13]</xref></p>
      </sec>
      <sec id="article-18191.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Behcet disease is&#x000a0;an auto-inflammatory vasculitis&#x000a0;involving arteries and veins of all sizes and types.&#x000a0;In contrast to other vasculitides, vasculitic lesions in Behcet disease lack&#x000a0;necrotizing vasculitis or giant cell formation. Venular involvement and formation of&#x000a0;pulmonary and arterial aneurysms are unique to Behcet disease.<xref ref-type="bibr" rid="article-18191.r14">[14]</xref> Furthermore, patients with Behcet disease lack specific autoantibodies, as seen in other autoimmune disorders such as systemic lupus erythematosus.</p>
        <p>Cell-mediated immunity plays a significant role in the pathogenesis of this disease.&#x000a0;Type 1 helper T (Th1) cell activation leads to increased circulating levels of T-lymphocytes, accounting for various symptoms of Behcet disease. Pro-inflammatory cytokines, including&#x000a0;IL-1, IL-8, IL-12, IL-17, IL-37, and TNF, are increased in&#x000a0;Behcet disease and are thought to be involved in the pathogenesis. They may also serve as an indicator of disease severity. Increased macrophage activation,&#x000a0;neutrophil chemotaxis, and phagocytosis have been observed in lesions of Behcet disease. Mucocutaneous lesions, including oral aphthae, skin pustules, and erythema nodosum, are thought to result from increased neutrophil activation leading to a neutrophilic vascular reaction that causes tissue injury.<xref ref-type="bibr" rid="article-18191.r15">[15]</xref> Circulating immune complexes play a role in causing the characteristic neutrophilic vascular reaction. Anti-endothelial cell antibodies and endothelial cell dysfunction are also thought to play a role in the pathogenesis of Behcet disease.<xref ref-type="bibr" rid="article-18191.r16">[16]</xref></p>
      </sec>
      <sec id="article-18191.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological features of the disease are vasculitis and thrombosis. Biopsy of the mucocutaneous lesions shows a neutrophil-predominant reaction with endothelial swelling, extravasation of RBCs, and leukocytoclastic vasculitis with fibrinoid necrosis of the blood vessel walls. The presence of lymphocytic vasculitis represents older lesions, and a neutrophilic vascular reaction is considered the most predominant reaction in Behcet disease. The involvement of vasa vasorum (vasculitis) may result in the formation of aneurysms in the large arteries.<xref ref-type="bibr" rid="article-18191.r17">[17]</xref> Synovial fluid analysis in Behcet disease reveals neutrophil-predominant leucocyte counts varying from 300 cells/mm^3 to more than 30,000 cells/mm^3.<xref ref-type="bibr" rid="article-18191.r18">[18]</xref></p>
      </sec>
      <sec id="article-18191.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>While mucocutaneous lesions are the hallmark of Behcet disease, the most severe manifestations are uveitis, large vessel, and neurological involvement.</p>
        <p>
<bold>Aphthae</bold>
</p>
        <p>Oral ulcers occur in 97% to 99% of patients with Behcet disease, often representing the initial clinical feature. Lesions are usually painful, recurrent, and multiple and may involve the soft palate, hard palate, buccal mucosa, tongue, gingiva, lips, and tonsils. More than 90% of oral ulcers heal without scarring.</p>
        <p>Genital lesions are seen in more than 80%&#x000a0;of patients with Behcet disease. These lesions are also recurrent, although, in contrast to oral lesions, more than 70% of genital lesions heal with scarring. Genital ulcers&#x000a0;occur on the scrotum (90%) in males and the vulva or vagina in females.</p>
        <p>
<bold>Cutaneous Manifestations</bold>
</p>
        <p>&#x000a0;Several cutaneous manifestations of Behcet disease have been described. Erythema nodosum-like lesions on the lower extremity are common. Behcet disease-related erythema nodosum lesions show a more vasculitic component compared to erythema nodosum, which is idiopathic or from other causes.<xref ref-type="bibr" rid="article-18191.r19">[19]</xref> Superficial thrombophlebitis appearing as nodular lesions may be associated with deep vein thrombosis.&#x000a0;Acneiform or pseudofolliculitis lesions are common but are non-specific and may be&#x000a0;indistinguishable from ordinary acne.<xref ref-type="bibr" rid="article-18191.r17">[17]</xref> Other cutaneous manifestations that have been described include&#x000a0;pyoderma gangrenosum-like lesions,&#x000a0;pustular vasculitic lesions,&#x000a0;cutaneous small-vessel vasculitis, and&#x000a0;Sweet syndrome-like lesions.</p>
        <p>A positive pathergy reaction characterized by the formation of erythematous papules or pustules 24 to 48 hours after needle insertion is thought to be very specific for Behcet disease.<xref ref-type="bibr" rid="article-18191.r20">[20]</xref>&#x000a0;While it is seen in 60% to 70% of patients from Turkey and Japan, a positive pathergy reaction is rarely observed in patients with Behcet disease who are from Northern Europe or the United States.<xref ref-type="bibr" rid="article-18191.r21">[21]</xref></p>
        <p>
<bold>Ocular Manifestations</bold>
</p>
        <p>More than 50% of patients with Behcet disease have eye involvement, although it is much more common in males and younger patients. Eye involvement is usually not the presenting feature of Behcet disease but usually occurs within the initial few years of diagnosis and is rare to occur late in the disease if not present earlier.<xref ref-type="bibr" rid="article-18191.r22">[22]</xref></p>
        <p>Uveitis that is relapsing, chronic, bilateral, and involves both anterior and posterior uveal tracts is common. Anterior uveitis causes erythema and photophobia, while posterior uveitis causes vision loss.&#x000a0;Hypopyon-related uveitis is less common but very severe, as it almost always accompanies severe retinal disease. Retinal involvement with retinal vasculitis can be seen as a cause of blindness in these patients. Conjunctivitis and isolated anterior uveitis are rare.&#x000a0;</p>
        <p>
<bold>Musculoskeletal Manifestations</bold>
</p>
        <p>Inflammatory, non-erosive, non-deforming arthritis is seen in 50% of patients with Behcet disease,&#x000a0;more common in patients with acneiform lesions.<xref ref-type="bibr" rid="article-18191.r23">[23]</xref> It is usually oligoarthritis that is symmetric or asymmetric, but polyarthritis and monoarthritis can also be seen. Joint involvement is peripheral, and spine involvement or sacroiliitis is not usually seen, differentiating it from HLA-B27-associated erosive sacroiliitis. The knees are the most commonly involved joint, followed by ankles, wrists, and elbows.<xref ref-type="bibr" rid="article-18191.r24">[24]</xref></p>
        <p>
<bold>Vascular Manifestations</bold>
</p>
        <p>The involvement of arterial and venous tracts of all sizes is a hallmark of Behcet disease and can be seen in 25% of patients, more commonly in males. The most common vascular manifestation is superficial and deep thrombophlebitis of the lower extremities. Rarely, Budd-Chiari syndrome or vena cava obstruction may be seen. Embolism of these thrombi is rare as the inflammatory thrombi tightly adhere to the diseased endothelium. Arterial vasculitis may involve any sized artery and be accompanied by aneurysms or occlusions. Aortitis and vasculitis of&#x000a0;the carotid, femoral, and popliteal arteries can be seen. Pulmonary artery involvement with aneurysm formation is unique to Behcet disease and is the leading cause of death in these patients.<xref ref-type="bibr" rid="article-18191.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Neurological Manifestations</bold>
</p>
        <p>Central nervous system involvement is seen in 5% to 10% of patients with Behcet disease, and 80% of it is parenchymal involvement, most commonly of the brainstem, that leads to cerebellar, pyramidal, and sensory signs and symptoms. The cerebrospinal&#x000a0;fluid examination is sterile but may reveal elevated protein and/or cell count. Nonparenchymal involvement characterized by dural sinus thrombi is seen in 20% and leads to headaches and papilledema. Simultaneous parenchymal and nonparenchymal involvement, isolated cerebellar involvement, and&#x000a0;cranial and peripheral nerve involvement are rare.<xref ref-type="bibr" rid="article-18191.r26">[26]</xref></p>
        <p>
<bold>Gastrointestinal Manifestations</bold>
</p>
        <p>Mucosal ulcerations resembling the orogenital aphthae can be seen in the terminal ileum, cecum, colon, and esophagus. Extensive ulcerations, especially ileocecal lesions, may lead to perforation. Inflammatory bowel disease can present with similar gastrointestinal features in addition to extragastrointestinal features, including uveitis, erythema nodosum, oral ulcers, inflammatory arthritis, and pyoderma gangrenosum; and needs to be ruled out before confirming a diagnosis of Behcet disease.</p>
        <p>
<bold>Other Systemic Manifestations</bold>
</p>
        <p>Cardiac involvement has been reported,&#x000a0;including pericarditis, myocarditis, endocarditis, coronary artery vasculitis, and coronary aneurysms.&#x000a0;Renal involvement is rare and may include AA-amyloidosis and glomerulonephritis. Epididymitis can also be seen.</p>
      </sec>
      <sec id="article-18191.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of Behcet is clinical and can be difficult due to the lack of any pathognomic laboratory findings.&#x000a0;Laboratory findings are usually non-specific, including anemia of chronic disease, leukocytosis, and elevation in markers of inflammation. Imaging studies shall be directed at the organ involved and may include X-rays and arthrocentesis to assess arthritis, CT-scan to assess for&#x000a0;bleeding, thrombosis, and ischemia, angiography to look for aneurysms and lumbar puncture to evaluate meningitis. The&#x000a0;rationale for carrying out these investigations&#x000a0;is to rule out other causes of the clinical presentation. A careful ophthalmologic examination to evaluate ocular involvement shall be pursued at the initial presentation, and cutaneous lesions shall be biopsied&#x000a0;to confirm the cutaneous diagnosis.</p>
        <p>Although several classification criteria have been published, they shall be used cautiously in the clinical setting to make a diagnosis. The International Team for the Revision of International Criteria for Beh&#x000e7;et Disease (ITR-ICBD) revised the established criteria in 2008. The revised criteria are point-based and give 1 point each to oral aphthosis, skin manifestations (pseudofolliculitis, skin aphthosis), vascular lesions (phlebitis, large vein thrombosis, aneurysm, arterial thrombosis), positive pathergy test and 2 points each to genital aphthosis and ocular lesions. Three or more points are needed for the diagnosis of Behcet disease. Similar to previous classification criteria, there are also some pitfalls with this criteria.</p>
        <p>Patients with inflammatory bowel disease, systemic lupus erythematosus, reactive arthritis, and herpetic infections can mimic Behcet disease and shall be ruled out first.</p>
      </sec>
      <sec id="article-18191.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Mucocutaneous Manifestations</bold>
</p>
        <p>
<bold>Isolated oral and genital aphthae:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial treatment with topical triamcinolone&#x000a0;acetonide cream 3&#x000a0;to 4 times a day until the pain from the ulcer is relieved<xref ref-type="bibr" rid="article-18191.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Topical sucralfate 1g/5mL four times daily&#x000a0;with or as an alternative to topical corticosteroids<xref ref-type="bibr" rid="article-18191.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Topical anesthetics, generally not as effective as steroids or sucralfate, can also provide temporary relief</p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;Prevention of recurrent oral and genital ulcers:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Colchicine 1 to 2 mg/day in divided doses
<list list-type="bullet"><list-item><p>First-line drug&#x000a0;</p></list-item><list-item><p>Doses in the range of 1.2 to 1.8 mg can be used when 0.5 mg tablets are unavailable.<xref ref-type="bibr" rid="article-18191.r29">[29]</xref></p></list-item><list-item><p>More effective in genital ulcers.</p></list-item><list-item><p>Has a narrow therapeutic index.</p></list-item><list-item><p>Cytopenias are a significant side effect.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Apremilast is titrated at a rate of 10 mg daily over six days to attain a maintenance dose of 30 mg twice daily.<xref ref-type="bibr" rid="article-18191.r30">[30]</xref>
<list list-type="bullet"><list-item><p>More effective in oral ulcers.</p></list-item><list-item><p>Adverse events include nausea, diarrhea, and headache.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Multiple lesions or isolated oral aphthae or genital ulcers are refractory to the therapy mentioned above:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prednisone 15 mg/day, tapering to 10 mg/day after one week and completing the course over a two- to three-week period
<list list-type="bullet"><list-item><p>Low-dose prednisone (e.g., 5 mg/day) with a prolonged course may be used in case of&#x000a0;recurrent oral aphthae</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>When all the treatment mentioned above fails:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Azathioprine
<list list-type="bullet"><list-item><p>The initial dose of&#x000a0;azathioprine is 50 mg daily.</p></list-item><list-item><p>As tolerated, increase the daily dose by 50 mg every four weeks.</p></list-item><list-item><p>The target dose is 2.5 mg/kg/day.</p></list-item><list-item><p>Complete blood count (CBC) is monitored&#x000a0;every two weeks initially till the maximum required dose is achieved and then every 6 to 12 weeks.</p></list-item><list-item><p>A lower dose is used in case of renal compromise.</p></list-item><list-item><p>Genetic testing for&#x000a0;thiopurine methyltransferase is advised before starting therapy. A deficiency of&#x000a0;thiopurine methyltransferase can cause an increased risk of developing severe, potentially life-threatening bone marrow toxicity with conventional doses of azathioprine or mercaptopurine.<xref ref-type="bibr" rid="article-18191.r31">[31]</xref></p></list-item><list-item><p>It can be combined with tumor necrosis factor (TNF)-alpha inhibitors (infliximab, adalimumab, etanercept)<xref ref-type="bibr" rid="article-18191.r32">[32]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Interferon
<list list-type="bullet"><list-item><p>Interferon alfa-2a and&#x000a0;Interferon alfa-2b (generally given 3 to 6 million units three times weekly)<xref ref-type="bibr" rid="article-18191.r33">[33]</xref><xref ref-type="bibr" rid="article-18191.r34">[34]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Cutaneous lesions (except erythema nodosum and pyoderma gangrenosum):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild:
<list list-type="bullet"><list-item><p>Colchicine&#x000a0;1 to 2 mg daily in divided dose</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Lesions unresponsive to colchicine:
<list list-type="bullet"><list-item><p>Prednisolone&#x000a0;up to 40 mg/day initially and a maintenance dose of 5 and 10 mg/day</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Erythema nodosum:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial therapy is a combination of oral prednisone&#x000a0;&#x000a0;(40 to 60 mg daily) and&#x000a0;azathioprine.
<list list-type="bullet"><list-item><p>The initial dose of&#x000a0;azathioprine is 50 mg daily.</p></list-item><list-item><p>As tolerated, increase the daily dose by 50 mg every four weeks.</p></list-item><list-item><p>The target dose is 2.5 mg/kg/day.</p></list-item><list-item><p>Complete blood count (CBC) is monitored&#x000a0;every two weeks initially till the maximum required dose is achieved and then every 6 to 12 weeks.</p></list-item><list-item><p>The initial prednisone dose&#x000a0;is administered for one month and then tapered gradually to complete the course over three to four months.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pyoderma gangrenosum (PG):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Extensive debridement is discouraged.</p>
          </list-item>
          <list-item>
            <p>Sterile saline or a mild antiseptic for wound care
<list list-type="bullet"><list-item><p>&#x000a0;Mild, localized PG:
<list list-type="bullet"><list-item><p>Topical corticosteroid (high potency or superpotent) or topical tacrolimus (0.03% to 0.3%)<xref ref-type="bibr" rid="article-18191.r35">[35]</xref></p></list-item></list>
</p></list-item><list-item><p>More extensive or rapidly progressing PG:
<list list-type="bullet"><list-item><p>Systemic glucocorticoids
<list list-type="bullet"><list-item><p>Oral prednisolone&#x000a0;(0.5 to 1.5 mg/kg per day) or its equivalent is started initially, with a maximum daily dose of 60 mg.</p></list-item><list-item><p>Intravenous pulse therapy with 1 g methylprednisolone daily&#x000a0;for one to five days can be started initially for&#x000a0;very aggressive or painful disease.<xref ref-type="bibr" rid="article-18191.r36">[36]</xref></p></list-item><list-item><p>Taper off glucocorticoids within 4 to 10 weeks and monitor closely for continued improvement or adverse effects.</p></list-item></list>
</p></list-item><list-item><p>Systemic cyclosporine
<list list-type="bullet"><list-item><p>Alternative for glucocorticoid intolerant or glucocorticoid unresponsive cases.<xref ref-type="bibr" rid="article-18191.r37">[37]</xref></p></list-item><list-item><p>Initiated at a dose of 4 to 5 mg/kg and subsequently tapered as tolerated</p></list-item><list-item><p>Treatment is limited to less than one year due to side effects, such as hypertension and renal toxicity</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Arthritis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial treatment:
<list list-type="bullet"><list-item><p>Colchicine 1 to 2 mg/day in divided doses<xref ref-type="bibr" rid="article-18191.r38">[38]</xref></p></list-item><list-item><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) for symptomatic pain relief</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Uncontrolled with colchicine:
<list list-type="bullet"><list-item><p>Prednisone 10 mg/day is initiated.</p></list-item><list-item><p>Low-dose prednisone (e.g., 5 mg/day or lower) when a prolonged course may be required</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Refractory or persistent arthritis:
<list list-type="bullet"><list-item><p>Azathioprine and/or TNF-alpha inhibitors</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Refractory to the therapy mentioned above:
<list list-type="bullet"><list-item><p>Interferon alfa or methotrexate<xref ref-type="bibr" rid="article-18191.r39">[39]</xref></p></list-item><list-item><p>Apremilast<xref ref-type="bibr" rid="article-18191.r40">[40]</xref><xref ref-type="bibr" rid="article-18191.r41">[41]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal Disease</bold>
</p>
        <p>
<bold>Gastrointestinal ulceration:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Glucocorticoids plus azathioprine
<list list-type="bullet"><list-item><p>Starting dose of prednisone&#x000a0;0.5 to 1 mg/kg daily<xref ref-type="bibr" rid="article-18191.r42">[42]</xref>
<list list-type="bullet"><list-item><p>Given for at least one month or until the resolution of symptoms improve</p></list-item><list-item><p>Decrease the daily dose to 10 mg/day over two to three months.</p></list-item></list>
</p></list-item><list-item><p>Azathioprine started at the same time as&#x000a0;prednisone
<list list-type="bullet"><list-item><p>The initial dose of&#x000a0;azathioprine is 50 mg daily.</p></list-item><list-item><p>As tolerated, increase the daily dose by 50 mg every four weeks.</p></list-item><list-item><p>The target dose is 2.5 mg/kg/day.</p></list-item><list-item><p>Complete blood count (CBC) is monitored&#x000a0;every two weeks initially till the maximum required dose is achieved and then every 6 to 12 weeks.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>TNF-alpha inhibitors<xref ref-type="bibr" rid="article-18191.r43">[43]</xref>
<list list-type="bullet"><list-item><p>Used when patients do not respond to glucocorticoids plus azathioprine</p></list-item><list-item><p>Infliximab and adalimumab have been used successfully.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Renal disease</bold>
</p>
        <p>
<bold>Minimal or mild nephritis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No specific therapy is indicated</p>
          </list-item>
        </list>
        <p>
<bold>Secondary&#x000a0;amyloidosis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Colchicine 1 to 1.2 mg daily</p>
          </list-item>
        </list>
        <p>
<bold>Ocular Involvement</bold>
</p>
        <p>
<bold>Anterior uveitis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial therapy:
<list list-type="bullet"><list-item><p>Topical corticosteroids (scopolamine 0.25% or cyclopentolate 1%</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Unresponsive to initial therapy:
<list list-type="bullet"><list-item><p>Prednisone at a starting dose of 40 mg and may be tapered to discontinuation over one month.<xref ref-type="bibr" rid="article-18191.r44">[44]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Posterior uveitis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial therapy:
<list list-type="bullet"><list-item><p>&#x000a0;Combination of oral prednisone and&#x000a0;azathioprine
<list list-type="bullet"><list-item><p>Starting dose of prednisone&#x000a0;1 mg/kg per day for one month and tapering as tolerated</p></list-item><list-item><p>Methylprednisolone as pulse therapy at a dose of 1 g/day for three days may be used empirically to save the sight.</p></list-item><list-item><p>The initial dose of&#x000a0;azathioprine is 50 mg daily.</p></list-item><list-item><p>As tolerated, increase the daily dose by 50 mg every four weeks.</p></list-item><list-item><p>The target dose is 2.5 mg/kg/day.</p></list-item><list-item><p>Complete blood count (CBC) is monitored&#x000a0;every two weeks initially till the maximum required dose is achieved and then every 6 to 12 weeks.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Severe or refractory disease:
<list list-type="bullet"><list-item><p>Infliximab and adalimumab have been used successfully.<xref ref-type="bibr" rid="article-18191.r45">[45]</xref></p></list-item><list-item><p>The initial dose of infliximab is 5 mg/kg at 0, 4, 8, 16, and 24 weeks or 0, 2, 6, and every eight weeks.</p></list-item><list-item><p>Adalimumab is given at a loading dose of 80 mg, followed by 40 mg one week later and 40 mg every two weeks thereafter.<xref ref-type="bibr" rid="article-18191.r46">[46]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Vascular Disease</bold>
</p>
        <p>
<bold>Large artery disease:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>High-dose glucocorticoids and cyclophosphamide</p>
          </list-item>
          <list-item>
            <p>Interventions or surgeries should preferably be done when the disease is not active.</p>
          </list-item>
        </list>
        <p>
<bold>Venous thrombosis:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Data does not support using&#x000a0;anticoagulant, antiplatelet, or fibrinolytic agents in patients with&#x000a0;thrombosis.</p>
          </list-item>
          <list-item>
            <p>Anticoagulation may be recommended case by case bases in&#x000a0;patients with Beh&#x000e7;et-associated dural sinus thrombi.<xref ref-type="bibr" rid="article-18191.r47">[47]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment includes glucocorticoids with another immunosuppressive agent as prescribed for posterior uveitis.</p>
          </list-item>
        </list>
        <p>
<bold>Neurologic Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment includes high-dose glucocorticoids with another immunosuppressive agent as prescribed for posterior uveitis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18191.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Behcet disease is a clinical diagnosis. However, the other diseases can mimic clinical features seen in Behcet disease, all of which should be ruled out before confirming a diagnosis of Behcet disease.</p>
        <list list-type="order">
          <list-item>
            <p>Inflammatory bowel disease (IBD):&#x000a0;In addition to gastrointestinal involvement, IBD and Behcet disease share several similar clinical features, which include oral ulcers, uveitis, inflammatory arthritis, erythema nodosum, and pyoderma gangrenosum. Colon biopsies may not be adequate in differentiating these diseases. However, sacroiliitis and axial inflammatory arthritis can be seen in IBD but not in Behcet disease. Posterior uveitis and panuveitis are rare in IBD. Vascular inflammation leading to aneurysms, venous thrombosis, CNS involvement, and pathergy test are also features of IBD. Without these other extra-gastrointestinal clinical features, it is challenging&#x000a0;to differentiate these two conditions.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Seronegative arthritis:&#x000a0;Reactive arthritis is another major differential diagnosis, as it can also cause peripheral inflammatory arthritis, ocular inflammation, and skin disease. As in IBD, posterior uveitis and panuveitis are rare in reactive arthritis, and vascular or CNS involvement is also rare. Sacroiliitis and axial involvement are common in reactive arthritis, while not in Behcet disease. Urethritis, penile lesions on the glans penis, and conjunctivitis, which are features of reactive arthritis, are not usually seen in Behcet disease.</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus (SLE):&#x000a0;SLE can have a very similar presentation to Behcet disease and can involve all the organs similarly involved in Behcet disease. However, inflammatory thrombi are not usually seen in SLE; the SLE-specific autoantibodies can help differentiate these two conditions.</p>
          </list-item>
          <list-item>
            <p>Herpetic infections:&#x000a0;Oral and genital lesions can be seen in herpetic infections, and when appropriate, a culture shall be done from the lesion to rule out herpes before considering Behcet.</p>
          </list-item>
          <list-item>
            <p>Beh&#x000e7;et-type disease manifests in patients treated with interleukin (IL) 17 inhibitors.<xref ref-type="bibr" rid="article-18191.r48">[48]</xref></p>
          </list-item>
        </list>
        <p>Other differential diagnoses that shall be considered (depending on organ involvement) include sarcoidosis, other systemic vasculitides, relapsing polychondritis, and multiple sclerosis.</p>
      </sec>
      <sec id="article-18191.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Behcet disease has no cure and is associated with significant morbidity and mortality. Poor prognosis and higher mortality are related to the male sex and younger&#x000a0;age of onset. Major causes of mortality include ruptured pulmonary and peripheral aneurysms and neurologic and gastrointestinal involvement. Renal involvement, especially amyloidosis, also carries a poor prognosis. However, more than 60% of patients go into remission after passing the initial years when the disease is most active. In addition, most patients eventually show improvement in disease flares, morbidity, and mortality.</p>
      </sec>
      <sec id="article-18191.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Besides increased mortality, Behcet disease is associated with several potential lifelong complications, most of which result from ocular or neurologic involvement. Patients with hypopyon-related uveitis and retinal involvement are at a high risk of blindness.</p>
          </list-item>
          <list-item>
            <p>Coronary or pulmonary arterial aneurysmal rupture is also associated with Behcet disease, which carries a high mortality risk.</p>
          </list-item>
          <list-item>
            <p>Centraal nervous involvement can lead to significant morbidity, permanent deficits, and death. Ocular involvement as anterior and posterior uveitis may result in permanent blindness.</p>
          </list-item>
          <list-item>
            <p>Another complication of Behcet disease is an increased incidence of miscarriages due to the vasculitis of the placenta.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18191.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should know there is no cure for&#x000a0;Beh&#x000e7;et syndrome, and symptoms can be controlled significantly with the prescribed drugs. As some drugs may be teratogenic, patients should discuss planning pregnancy before starting treatment. Patients should be explained the variety of symptoms they may experience and encouraged to seek immediate medical attention in case any of these symptoms appear so that their medications may be switched if needed.</p>
      </sec>
      <sec id="article-18191.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Early diagnosis and recognition of organ involvement with immediate intervention can help decrease the morbidity and mortality in Behcet disease.</p>
          </list-item>
          <list-item>
            <p>Treatment varies according to the patient's sex, presentation, and preference.</p>
          </list-item>
          <list-item>
            <p>The duration of treatment is not known. However, immunosuppressive therapy for at least 18 to 24 months is usually recommended in refractory illness.</p>
          </list-item>
          <list-item>
            <p>Hematopoietic stem cell transplantation and granulocytapheresis are being investigated as therapy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18191.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Because of the diverse presentation of Behcet disease, it is best managed by an interprofessional healthcare team that consists of an ophthalmologist, rheumatologist, internist, cardiologist, neurologist, dermatologist, vascular surgeon, and gastroenterologist. Nursing and pharmacists round out the team. There is no cure for the disease, and treatment is aimed at preventing organ damage. The disorder is not easy to diagnose and often requires consultation from multiple specialists. Each of these specialists must&#x000a0;document and share their findings and recommendations with the rest of the interprofessional team.</p>
        <p>Besides corticosteroids, these patients need other anti-inflammatory or immunosuppressive agents. The pharmacist should educate the patient on the importance of medication compliance and signs of adverse events so they can call the pharmacist or the prescriber. In addition, the involvement of the wound care team may be needed in patients who develop skin ulcers, fistulas, and rashes. Nurses can counsel the patients on their condition, advise them on wound care, and review what symptoms should prompt a call to the appropriate clinician. Surgery may sometimes be required as well. Because the condition is rare in North America, the team should be in close communication, which may be vital to preventing complications of Behcet disease. [Level 5]</p>
      </sec>
      <sec id="article-18191.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18191&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18191">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/behcet-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18191">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18191/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18191">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18191.s17">
        <title>References</title>
        <ref id="article-18191.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FEIGENBAUM</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Description of Beh&#x000e7;et's syndrome in the Hippocratic third book of endemic diseases.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1956</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>355</fpage>
            <page-range>355-7</page-range>
            <pub-id pub-id-type="pmid">13355940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Menthon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lavalley</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Maldini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>HLA-B51/B5 and the risk of Beh&#x000e7;et's disease: a systematic review and meta-analysis of case-control genetic association studies.</article-title>
            <source>Arthritis Rheum</source>
            <year>2009</year>
            <month>Oct</month>
            <day>15</day>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>1287</fpage>
            <page-range>1287-96</page-range>
            <pub-id pub-id-type="pmid">19790126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Direskeneli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saruhan-Direskeneli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The role of heat shock proteins in Beh&#x000e7;et's disease.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2003</year>
            <season>Jul-Aug</season>
            <volume>21</volume>
            <issue>4 Suppl 30</issue>
            <fpage>S44</fpage>
            <page-range>S44-8</page-range>
            <pub-id pub-id-type="pmid">14727460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mizushima</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Beh&#x000e7;et's disease.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-5</page-range>
            <pub-id pub-id-type="pmid">2043450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isogai</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kotake</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isogai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsurumizu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yokota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Syuto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Chemiluminescence of neutrophils from patients with Beh&#x000e7;et's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora.</article-title>
            <source>Arch Oral Biol</source>
            <year>1990</year>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-8</page-range>
            <pub-id pub-id-type="pmid">2117912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatemi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bahar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Uysal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gogus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Masatlioglu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Altas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The pustular skin lesions in Behcet's syndrome are not sterile.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>11</issue>
            <fpage>1450</fpage>
            <page-range>1450-2</page-range>
            <pub-id pub-id-type="pmid">15479894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karincaoglu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Borlu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toker</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Akman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Onder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gunasti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kandi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Durusoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Seyhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Utas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saricaoglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozden</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Uzun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tursen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cicek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Donmez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Demographic and clinical properties of juvenile-onset Beh&#x000e7;et's disease: A controlled multicenter study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>579</fpage>
            <page-range>579-84</page-range>
            <pub-id pub-id-type="pmid">18045733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Treudler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orfanos</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Zouboulis</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Twenty-eight cases of juvenile-onset Adamantiades-Beh&#x000e7;et disease in Germany.</article-title>
            <source>Dermatology</source>
            <year>1999</year>
            <volume>199</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-9</page-range>
            <pub-id pub-id-type="pmid">10449951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pazarli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yurdakul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozyazgan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozdo&#x0011f;an</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Serdaro&#x0011f;lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ersanli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ulk&#x000fc;</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ft&#x000fc;o&#x0011f;lu</surname>
                <given-names>AU</given-names>
              </name>
            </person-group>
            <article-title>Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Beh&#x000e7;et's syndrome.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>783</fpage>
            <page-range>783-9</page-range>
            <pub-id pub-id-type="pmid">6524980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kon&#x000e9;-Paut</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Geisler</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ozen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ozdogan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rozenbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Familial aggregation in Beh&#x000e7;et's disease: high frequency in siblings and parents of pediatric probands.</article-title>
            <source>J Pediatr</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>135</volume>
            <issue>1</issue>
            <fpage>89</fpage>
            <page-range>89-93</page-range>
            <pub-id pub-id-type="pmid">10393610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;lbay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Acican</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Er&#x000e7;en Diken</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Pinar &#x000d6;nen</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Familial Beh&#x000e7;et's disease of adult age: a report of 4 cases from a Beh&#x000e7;et family.</article-title>
            <source>Intern Med</source>
            <year>2012</year>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>1609</fpage>
            <page-range>1609-11</page-range>
            <pub-id pub-id-type="pmid">22728500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azizlerli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>K&#x000f6;se</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Sarica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>G&#x000fc;l</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tutkun</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Kula&#x000e7;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tun&#x000e7;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Urgancio&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di&#x0015f;&#x000e7;i</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Beh&#x000e7;et's disease in Istanbul, Turkey.</article-title>
            <source>Int J Dermatol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>803</fpage>
            <page-range>803-6</page-range>
            <pub-id pub-id-type="pmid">14521694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calamia</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Icen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kremers</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and clinical characteristics of Beh&#x000e7;et's disease in the US: a population-based study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2009</year>
            <month>May</month>
            <day>15</day>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>600</fpage>
            <page-range>600-4</page-range>
            <pub-id pub-id-type="pmid">19405011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melikoglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kural-Seyahi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tascilar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The unique features of vasculitis in Beh&#x000e7;et's syndrome.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>1-2</issue>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">18172779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zouboulis</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of Adamantiades-Beh&#x000e7;et's disease.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2003</year>
            <volume>528</volume>
            <fpage>161</fpage>
            <page-range>161-71</page-range>
            <pub-id pub-id-type="pmid">12918684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Identification of HnRNP-A2/B1 as a target antigen of anti-endothelial cell IgA antibody in Beh&#x000e7;et's disease.</article-title>
            <source>J Invest Dermatol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>132</volume>
            <issue>3 Pt 1</issue>
            <fpage>601</fpage>
            <page-range>601-8</page-range>
            <pub-id pub-id-type="pmid">22205302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jorizzo</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Abernethy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Mangelsdorf</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Zouboulis</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sarica</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gaffney</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>al Ialaan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mucocutaneous criteria for the diagnosis of Beh&#x000e7;et's disease: an analysis of clinicopathologic data from multiple international centers.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>968</fpage>
            <page-range>968-76</page-range>
            <pub-id pub-id-type="pmid">7751467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yurdakul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pazarli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yal&#x000e7;in</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alta&#x000e7;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozyazgan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;ner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ft&#x000fc;o&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The arthritis of Beh&#x000e7;et's disease: a prospective study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1983</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>505</fpage>
            <page-range>505-15</page-range>
            <pub-id pub-id-type="pmid">6625699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demirkesen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;ner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Senocak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000fc;y&#x000fc;kbabani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic evaluation of nodular cutaneous lesions of Beh&#x000e7;et syndrome.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-6</page-range>
            <pub-id pub-id-type="pmid">11554161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Din&#x000e7;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karaayvaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caliskaner</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Pay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erdem</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dermographism and atopy in patients with Beh&#x000e7;et's disease.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2000</year>
            <season>Nov-Dec</season>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>368</fpage>
            <page-range>368-71</page-range>
            <pub-id pub-id-type="pmid">11206938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yurdakul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ft&#x000fc;oglu</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A comparative study of the pathergy reaction among Turkish and British patients with Beh&#x000e7;et's disease.</article-title>
            <source>Ann Rheum Dis</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-5</page-range>
            <pub-id pub-id-type="pmid">6696522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benezra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Treatment and visual prognosis in Beh&#x000e7;et's disease.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>70</volume>
            <issue>8</issue>
            <fpage>589</fpage>
            <page-range>589-92</page-range>
            <pub-id pub-id-type="pmid">3741823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karaca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hatemi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sut</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The papulopustular lesion/arthritis cluster of Beh&#x000e7;et's syndrome also clusters in families.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>1053</fpage>
            <page-range>1053-60</page-range>
            <pub-id pub-id-type="pmid">22286924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaklamani</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Vaiopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaklamanis</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Beh&#x000e7;et's Disease.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>197</fpage>
            <page-range>197-217</page-range>
            <pub-id pub-id-type="pmid">9514126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamuryudan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Er</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seyahi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Akman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fresko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yurdakul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Numan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary artery aneurysms in Beh&#x000e7;et syndrome.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Dec</month>
            <day>01</day>
            <volume>117</volume>
            <issue>11</issue>
            <fpage>867</fpage>
            <page-range>867-70</page-range>
            <pub-id pub-id-type="pmid">15589493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Araji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Neuro-Beh&#x000e7;et's disease: epidemiology, clinical characteristics, and management.</article-title>
            <source>Lancet Neurol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-204</page-range>
            <pub-id pub-id-type="pmid">19161910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fani</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ebrahimi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pourshahidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aflaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shafiee Sarvestani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparing the Effect of Phenytoin Syrup and Triamcinolone Acetonide Ointment on Aphthous Ulcers in Patients with Behcet's Syndrome.</article-title>
            <source>Iran Red Crescent Med J</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>75</fpage>
            <page-range>75-8</page-range>
            <pub-id pub-id-type="pmid">22737559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Er</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Durusoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The use of sucralfate suspension in the treatment of oral and genital ulceration of Beh&#x000e7;et disease: a randomized, placebo-controlled, double-blind study.</article-title>
            <source>Arch Dermatol</source>
            <year>1999</year>
            <month>May</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>529</fpage>
            <page-range>529-32</page-range>
            <pub-id pub-id-type="pmid">10328192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davatchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sadeghi Abdollahi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tehrani Banihashemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shahram</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nadji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shams</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chams-Davatchi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Colchicine versus placebo in Beh&#x000e7;et's disease: randomized, double-blind, controlled crossover trial.</article-title>
            <source>Mod Rheumatol</source>
            <year>2009</year>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>542</fpage>
            <page-range>542-9</page-range>
            <pub-id pub-id-type="pmid">19597921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatemi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Seyahi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fresko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Talarico</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hamuryudan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Beh&#x000e7;et's syndrome: a critical digest of the 2014-2015 literature.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>33</volume>
            <issue>6 Suppl 94</issue>
            <fpage>S3</fpage>
            <page-range>S3-14</page-range>
            <pub-id pub-id-type="pmid">26487500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casaj&#x000fa;s</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zubiaur</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000e9;ndez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campod&#x000f3;nico</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navares-G&#x000f3;mez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villapalos-Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soria-Chacartegui</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Novalbos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rom&#x000e1;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mej&#x000ed;a-Abril</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ochoa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abad-Santos</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers.</article-title>
            <source>Adv Ther</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>1743</fpage>
            <page-range>1743-1753</page-range>
            <pub-id pub-id-type="pmid">35192152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arida</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fragiadaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Giavri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sfikakis</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Anti-TNF agents for Beh&#x000e7;et's disease: analysis of published data on 369 patients.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-70</page-range>
            <pub-id pub-id-type="pmid">21168186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000f6;tter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>G&#x000fc;naydin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zierhut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St&#x000fc;biger</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The use of interferon alpha in Beh&#x000e7;et disease: review of the literature.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>320</fpage>
            <page-range>320-35</page-range>
            <pub-id pub-id-type="pmid">15079763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpsoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Durusoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ozgurel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ermis</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yazar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basaran</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Interferon alfa-2a in the treatment of Beh&#x000e7;et disease: a randomized placebo-controlled and double-blind study.</article-title>
            <source>Arch Dermatol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>138</volume>
            <issue>4</issue>
            <fpage>467</fpage>
            <page-range>467-71</page-range>
            <pub-id pub-id-type="pmid">11939808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Ormerod</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Greenlaw</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Norrie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Wahie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>HC</given-names>
              </name>
              <collab>UK Dermatology Clinical Trials Network's STOP GAP Team</collab>
            </person-group>
            <article-title>Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>940</fpage>
            <page-range>940-949</page-range>
            <pub-id pub-id-type="pmid">27502313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prystowsky</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Present status of pyoderma gangrenosum. Review of 21 cases.</article-title>
            <source>Arch Dermatol</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">2642682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reichrath</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonowitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tilgen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-83</page-range>
            <pub-id pub-id-type="pmid">16021123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yurdakul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000fc;z&#x000fc;n</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozyazgan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hamuryudan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Uysal</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Senocak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A double-blind trial of colchicine in Beh&#x000e7;et's syndrome.</article-title>
            <source>Arthritis Rheum</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>2686</fpage>
            <page-range>2686-92</page-range>
            <pub-id pub-id-type="pmid">11710724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yal&#x000e7;inda&#x0011f;</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Uzun</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Results of interferon alpha-2a therapy in patients with Behcet's disease.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-43</page-range>
            <pub-id pub-id-type="pmid">22455657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buffier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vautier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Joncour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jamilloux</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gerfaud-Valentin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouillet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lazaro</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Misery</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gobert</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goulenok</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sacre</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>S&#x000e8;ve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Comarmond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saadoun</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Apremilast in Refractory Beh&#x000e7;et's Syndrome: A Multicenter Observational Study.</article-title>
            <source>Front Immunol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>626792</fpage>
            <pub-id pub-id-type="pmid">33613571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atienza-Mateo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Varillas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gra&#x000f1;a</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Espinosa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moriano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Sandoval</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Armario</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Castellv&#x000ed;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rom&#x000e1;n-Ivorra</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oliv&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yb&#x000e1;&#x000f1;ez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez-Ferrer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Narv&#x000e1;ez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Romero-Yuste</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ojeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Loricera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Calvo-R&#x000ed;o</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Casta&#x000f1;eda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonzalez-Gay</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>R</given-names>
              </name>
              <collab>Spanish Collaborative Group of Refractory Beh&#x000e7;et's Disease</collab>
            </person-group>
            <article-title>Apremilast in refractory orogenital ulcers and other manifestations of Beh&#x000e7;et's disease. A national multicentre study of 51 cases in clinical practice.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>38 Suppl 127</volume>
            <issue>5</issue>
            <fpage>69</fpage>
            <page-range>69-75</page-range>
            <pub-id pub-id-type="pmid">33331268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Mazlumzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calamia</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal disease in Beh&#x000e7;et's disease.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2003</year>
            <volume>528</volume>
            <fpage>459</fpage>
            <page-range>459-64</page-range>
            <pub-id pub-id-type="pmid">12918744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kunisaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagahori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uchino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koganei</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takeno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mizuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hisamatsu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based diagnosis and clinical practice guidelines for intestinal Beh&#x000e7;et's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.</article-title>
            <source>J Gastroenterol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>679</fpage>
            <page-range>679-700</page-range>
            <pub-id pub-id-type="pmid">32377946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shahram</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shams</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akhlaghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashofteh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davatchi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>1269</fpage>
            <page-range>1269-1276</page-range>
            <pub-id pub-id-type="pmid">28524639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kamoi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mochizuki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh&#x000e7;et disease.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>284</fpage>
            <page-range>284-8</page-range>
            <pub-id pub-id-type="pmid">19692382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabiani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emmi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vannozzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lopalco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guerriero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Franceschini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bacherini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cimino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Soriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frediani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Galeazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iannone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tosi</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cantarini</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of adalimumab in Beh&#x000e7;et's disease-related uveitis: a multicenter retrospective observational study.</article-title>
            <source>Clin Rheumatol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <page-range>183-189</page-range>
            <pub-id pub-id-type="pmid">27853889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akman-Demir</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bohlega</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Borhani-Haghighi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Constantinescu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Houman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvarani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sfikakis</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Siva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Araji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of Neuro-Beh&#x000e7;et's disease: international consensus recommendations.</article-title>
            <source>J Neurol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>261</volume>
            <issue>9</issue>
            <fpage>1662</fpage>
            <page-range>1662-76</page-range>
            <pub-id pub-id-type="pmid">24366648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18191.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calleja Algarra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arag&#x000f3;n Miguel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s Lencina</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pinilla Mart&#x000ed;n</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vico Alonso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez Peralto</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ortiz Romero</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Rivera D&#x000ed;az</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Beh&#x000e7;et's-like disease during secukinumab treatment: new paradoxical reaction?</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-118</page-range>
            <pub-id pub-id-type="pmid">32776677</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
